BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30

• Business

  AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022

  AcelRx Pharmaceuticals, Inc. today announced that it will release third quarter financial results after market close on Monday, November 14, 2022.

  November 3, 2022

   · 

  2 min read
• Business

  Edgewise Therapeutics Reports Third Quarter 2022 Financial Results

  Edgewise Therapeutics, Inc. today reported financial results for the third quarter of 2022 and recent business highlights.

  November 3, 2022

   · 

  12 min read
• Biotech Bay

  OrsoBio Announces Presentation of Five Abstracts at AASLD’s The Liver Meeting® 2022 Highlighting Programs for Severe Metabolic Disorders

  OrsoBio Announces Presentation of Five Abstracts at AASLD’s The Liver Meeting ® 2022 Highlighting Programs for Severe Metabolic Disorders.

  November 3, 2022

   · 

  6 min read
• Genetown

  Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts on the company’s portfolio of cystic fibrosis (CF) medicines will be presented in posters and oral presentations at this year’s North American Cystic Fibrosis Conference.

  November 3, 2022

   · 

  11 min read
• Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events

  Cybin Inc. is pleased to announce its participation in the following upcoming investor events.

  November 3, 2022

   · 

  1 min read
• Business

  Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline

  Exelixis, Inc. (Nasdaq: EXEL) and Catalent, Inc. (NYSE: CTLT) today announced a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with lead antibody and/or ADC candidates.

  November 3, 2022

   · 

  9 min read
• Pharm Country

  Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences - November 03, 2022

  Phathom Pharmaceuticals, Inc. announced that members of its management team will participate in upcoming investor conferences.

  November 3, 2022

   · 

  2 min read
• Drug Development

  Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022

  Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leading neuroscience-focused biopharmaceutical company, today reported additional results from the Phase 3 KINECT-HD study investigating valbenazine for the treatment of chorea associated with Huntington Disease (HD).

  November 3, 2022

   · 

  8 min read
• Business

  Lisata Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time

  Lisata Therapeutics, Inc. announced that the Company will report its financial results for the three and nine months ended September 30, 2022, on Thursday, November 10, 2022, at 4:30 p.m..

  November 3, 2022

   · 

  2 min read
• Biotech Beach

  Aadi Bioscience to Present at Upcoming Investor Conferences

  Aadi Bioscience, Inc. today announced that the Company will be presenting and hosting one-on-one meetings at the following conferences during November.

  November 3, 2022

   · 

  1 min read